RecruitingNot ApplicableNCT06715839

Target-specific immunoPET Imaging of Digestive System Carcinoma

Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma

Sponsor

RenJi Hospital

Enrollment

400 participants

Start Date

Dec 4, 2024

Study Type

INTERVENTIONAL

Conditions

Malignancy Liver Cancer Pancreatic Cancer Colon Cancer Digestive System Carcinoma Esophagus Cancer Digestive Cancer Stomach Cancer Small Intestine Cancer Rectum Cancer Digestive System Neoplasm Digestive System Cancer Gallbladder Carcinoma Appendix Cancer Bile Duct Carcinoma

Summary

The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of PET scan imaging using a specially designed antibody to better detect and visualize cancers of the digestive system (including stomach, bowel, liver, and pancreatic cancers). The aim is to improve how these cancers are diagnosed and staged. **You may be eligible if...** - You are aged 18–75 (any sex) - You have a confirmed or suspected diagnosis of a digestive system cancer - You are able to give informed consent **You may NOT be eligible if...** - You are pregnant - You have severe liver or kidney failure - You have had major surgery in the past month - You are allergic to antibody-based imaging agents Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[68Ga]Ga-DOTA-H2D3

Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[68Ga\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-DOTA-H2D3 injection.

DRUG[18F]F-RESCA-RB14

Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[18F\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RB14 injection.

DRUG[68Ga]Ga-NOTA-T4

Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[68Ga\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.

DRUG[18F]F-RESCA-T4

Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[18F\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.

DRUG[68Ga]Ga-NOTA-G5

Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[68Ga\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-G5 injection.

DRUG[18F]F-RESCA-G5

Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[18F\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-G5 injection.

DRUG[68Ga]Ga-NOTA-WWH347

Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[68Ga\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-WWH347 injection.

DRUG[18F]F-RESCA-WWH347

Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[18F\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-WWH347 injection.

DRUG[68Ga]Ga-NOTA-RND20

Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[68Ga\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RND20 injection.

DRUG[18F]F-RESCA-RND20

Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[18F\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RND20 injection.